Investigation of mass-balance issue in e-beam sterilized paclitaxel eluting coronary stents by SPME/GC-MS.
Paclitaxel eluting coronary stents were sterilized by e-beam in a closed system, to investigate sterilization related mass-balance issues and evaluate potential volatile paclitaxel degradation products. A solid-phase microextraction (SPME) method utilizing a polydimethyl-siloxane/divinyl-benzene (PDMS/DVB) fiber was optimized for extracting the volatiles from the head-space of the sterilized stents. GC-MS was used for separation, identification, and quantitation of the components. Benzaldehyde and benzoic acid were identified as paclitaxel related volatile degradation products. Three groups of stents were included in the study, a control group (not exposed to e-beam), a group sterilized at 25 kGy, and a final group sterilized at 75 kGy. The stents sterilized by e-beam at 75 kGy contained significantly higher levels of benzoic acid relative to the controls and the stents at 25 kGy contained intermediate levels of benzoic acid. The benzaldehyde levels increased in the 25 kGy e-beam sterilized stents relative to the control but remained fairly constant in the 75 kGy e-beam sterilized stents relative to the 25 kGy e-beam results. Mechanism for the formation of benzoic acid and benzaldehyde from paclitaxel was proposed. The levels of benzoic acid and benzaldehyde observed on the stents did not resolve the original mass-balance issue, but most likely contribute to the lack of mass balance observed for paclitaxel.
Vas
György
G
Cordis Corporation, Convergent Product Development, Analytical Technologies, Welsh and McKean Roads, P.O. Box 776, Spring House, PA 19477-0776, USA. gvas@crdus.jnj.com
Alquier
Lori
L
Maryanoff
Cynthia A
CA
Cohen
Judith
J
Reed
Gail
G
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000737:chemistry; D003327:Coronary Disease / Q000473:pathology; D054855:Drug-Eluting Stents; D004583:Electrons; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D015394:Molecular Structure; D008970:Molecular Weight; D017239:Paclitaxel / Q000008:administration & dosage* / Q000737:chemistry; D052617:Solid Phase Microextraction / Q000379:methods*; D013242:Sterilization; D014835:Volatilization
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel